Revenue increased to $2,691,741 in 2025, up 26% from $2,131,926 in 2024. Gross profit rose to $1,810,849, with gross margin expanding to 67.3% from 63.7% in 2024. Achieved net income of $457,417 in 2025, a significant improvement from a net loss of $259,239 in 2024. Interest expense declined significantly to $237,413 from $465,055 in 2024 due to debt restructuring and extinguishment. Recorded a gain of approximately $1.15 million related to the extinguishment of convertible debt, strengthening the balance sheet. Cash increased to $636,157 at year-end 2025 compared to $157,168 at the end of 2024. Current liabilities were significantly reduced from approximately $2.4 million at December 31, 2024, to approximately $450,000 at December 31, 2025. Integrated Service Program (ISP) revenue grew 74% year-over-year to $1,121,134, reflecting continued adoption among primary care providers. Sales of immunotherapy treatments also increased approximately 19% year-over-year, contributing to revenue diversification.